# VK2735 — dosage, half-life & reference guide | PepVault

Source: https://pepvault.app/peptides/vk2735

Last updated: 2026-11-18

Use: © PepVault. Read and cite with a link. Copying, bulk scraping, rewriting or republishing is not permitted (https://pepvault.app/terms#content).

[Library](https://pepvault.app/peptides) [Metabolic & GLP-1](https://pepvault.app/peptides#metabolic)

# VK2735 Dosage, half-life & reference guide

Also known as VK-2735 · VK 2735

Reviewed November 2026 1 study Evidence: Moderate [Published by PepVault](https://pepvault.app/guides/how-we-research)

A weekly GLP-1 and GIP dual agonist from Viking Therapeutics, the same two-receptor approach as tirzepatide, also being tested as a daily tablet. In its 13-week phase 2 trial, people lost about 9% to 15% of their body weight depending on the dose, with no sign of levelling off.

- **Studied range:** 2.5–17.5 mg starting dose 2.5 mg
- **How often:** Weekly
- **Half-life:** ~9 days
- **Evidence:** Moderate
- **Route:** SubQ injection

Studied in research — not a recommendation.

[VK2735 dose guide](https://pepvault.app/lab/dosage/vk2735)

## How it works.

Once-weekly peptide that switches on both the GLP-1 and the GIP receptors, the same pair tirzepatide works through. A side chain stretches its half-life to about 7 to 10 days in people, long enough for weekly shots. The idea is the one tirzepatide proved: two incretin signals that curb appetite and food intake together. Viking also makes it as a daily tablet, the same molecule by mouth. Investigational, in phase 3 since June 2025.

**Commonly reported:** In trials, nausea and other GI effects early on, fading as the dose holds. It is in phase 3 and not approved anywhere.

### Half-life & active level

The half-life of VK2735 is ~9 days (measured in people: 170–250 hours after single doses, Viking phase 1, 2023).

Here's how a typical VK2735 schedule accumulates over four weeks (one-compartment estimate).

An estimate from the half-life above, not a measurement. See your own curve build live in [the half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator).

<!--promo-->

Model. Individual results vary.

PepVault for iPhone

## Track VK2735 in PepVault

Log each dose, see how many doses are left in the vial, and keep your step-ups in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=peptides-card-flow&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## Where VK2735 works.

- ### Appetite & metabolism

  **In people.** In its 13-week phase 2 trial, people lost about 9% to 15% of their body weight depending on the dose, with no sign of levelling off.

An area lights for what a peptide is used for and what people report, with the evidence beside it. It isn’t a promise that it works there.

## Week by week.

What to expect in the first 8 weeks

- **Onset:** Days–2 weeks
- **Peak effect:** 78 weeks (phase 3 endpoint, not yet read out)
- **Duration:** Ongoing

1. Day 1–21 · 2.5 mg RCT

   ### Low start, first weeks

   You're on 2.5 mg, where most of the phase 2 trial began. Commonly reported: appetite dropping within days. In that trial, GI side effects came early and faded, and the group that skipped this start had the worst first-week nausea.

   The science

   VENTURE (Bays 2026, Obesity; 176 adults without diabetes): all groups started at 2.5 mg except the 15 mg group, which started at 5.0 mg; nausea was highest in that group's first week, and GI AEs "were generally observed early in the study and subsided over time". The authors: "The clear benefit of starting below 5.0 mg and titrating up has informed the phase 3 trial design".

   Sources

   - Bays et al. (VENTURE) (2026)

   Updated Nov 2026
2. Day 22–91 RCT

   ### The first 13 weeks

   In the phase 2 trial, every dose took off weight quickly: about 9% on the lowest and 15% on the highest by week 13, against about 2% on placebo. Nearly everyone on the drug lost at least 5%.

   The science

   VENTURE week 13 (mITT, MMRM): 2.5 mg −9.1%, 5 mg −10.9%, 10 mg −12.9%, 15 mg −14.7% vs −1.7% on placebo (all p < 0.0001); 9.2 to 14.6 kg; 93% (130/140) reached at least 5% loss vs 12% (4/34) on placebo (Bays 2026). Viking reported no sign of a plateau at week 13.

   Sources

   - Bays et al. (VENTURE) (2026)

   Updated Nov 2026
3. Day 22–546 · 7.5 mg RCT

   ### The lowest phase 3 dose

   You're at 7.5 mg, the lowest of the three doses in the phase 3 trials. In phase 2, doses around here took off about 11% to 13% in 13 weeks. Commonly reported: appetite control holding, with GI effects quieter once the dose stays put.

   The science

   VANQUISH-1 and -2 randomize to 7.5, 12.5 or 17.5 mg weekly or placebo for 78 weeks (Viking, Oct-28-2026; NCT07104500, NCT07104383). VENTURE's neighbouring doses: 5 mg −10.9% and 10 mg −12.9% at week 13 (Bays 2026). Phase 3 results are expected after its primary completion (estimated Jul-2027).

   Sources

   - Bays et al. (VENTURE) (2026)
   - Viking (Q3 2026 update) (2026)

   Updated Nov 2026
4. Day 43–546 · 12.5 mg RCT

   ### The middle phase 3 dose

   You're at 12.5 mg, the middle phase 3 dose. In phase 2, 10 mg and 15 mg took off about 13% and 15% in 13 weeks. GI side effects were more common at the higher doses, mostly early.

   The science

   VENTURE TEAEs, 10 mg vs 15 mg vs placebo: any GI 71% / 83% / 37%; nausea 37% / 63% / 20%; vomiting 17% / 29% / 0; stopped for an AE 11% / 20% / 0 (Bays 2026).

   Sources

   - Bays et al. (VENTURE) (2026)

   Updated Nov 2026
5. Day 43–546 · 17.5 mg Clinical

   ### The top phase 3 dose

   You're at 17.5 mg, the highest phase 3 dose. In Viking's maintenance study, a group kept on 17.5 mg weekly reached about 22% average loss by week 33 and was still losing.

   The science

   Maintenance study Part 1 (180 adults with a BMI of 30 or more, no comorbidities; 21-week induction at 15 to 22.5 mg weekly, titrated every 2 weeks): week-21 loss about 16% to 19% vs about 0% on placebo; 98% reached 5%, 90% 10%, 65% 15% and 32% 20%. An exploratory group on 17.5 mg weekly through week 33 reached about 22% with no plateau (Viking, Oct-28-2026; topline, not yet a paper).

   Sources

   - Viking (Q3 2026 update) (2026)

   Updated Nov 2026
6. Any day RCT

   ### What VK2735 is built on

   A phase 1 trial, a 13-week phase 2 trial of the shot, a 13-week phase 2 trial of the tablet, and a maintenance study. Two phase 3 programs are running: VANQUISH for the shot since 2025 and SUNRISE for the tablet since late 2026. It is not approved anywhere.

   The science

   Phase 1 SAD/MAD in Australia (NCT05203237): half-life 170 to 250 hours after single shots, up to 7.8% loss from baseline after 28 days (Viking, Mar-28-2023). VENTURE (Bays 2026; NCT06068946, sponsor Viking, 20 US sites). VENTURE-Oral (NCT06828055): up to 12.2% at 13 weeks on daily tablets, GI events similar to placebo (Viking, Oct-28-2026). Phase 3: VANQUISH-1 (NCT07104500, ~4,500, 78 weeks), VANQUISH-2 (NCT07104383, with type 2 diabetes); SUNRISE-1 and -2 (tablet: 27.5, 35 or 55 mg daily, 68 weeks).

   Sources

   - Viking (phase 1 release) (2023)
   - Bays et al. (VENTURE) (2026)
   - Viking (Q3 2026 update) (2026)

   Updated Nov 2026
7. With BPC-157 Community

   ### Why people add BPC-157 to a GLP-1

   GI side effects come mostly early, and BPC-157, first studied as a stomach-protecting peptide, is added to ease them. Commonly reported: smoother first weeks. No trial has tested the pair.

   The science

   BPC-157's early research was on gastric protection in animal studies (Sikiric 2018 review). No trial has tested it alongside VK2735 or any GLP-1 drug; the pairing comes from community reports.

   Sources

   - Sikiric et al. (2018)

   Updated Nov 2026

### After week 8

1. Day 150+ Clinical

   ### Holding the loss on fewer shots

   Viking is testing whether a shot every other week or once a month can hold the loss. In its first maintenance study, people kept 82% to 97% of their loss over 12 weeks on the less frequent shots, against 61% on placebo. Continue, space out or stop is a call for you and your clinician.

   The science

   After 21 weekly doses, groups moved to every-other-week dosing (83% to 97% of the loss retained at week 33) or monthly dosing (82% to 90%) vs 61% after switching from 17.5 mg weekly to placebo (each p < 0.01); GI events in the maintenance period were low (Viking, Oct-28-2026). Part 2, with daily tablet options, is running. Topline only.

   Sources

   - Viking (Q3 2026 update) (2026)

   Updated Nov 2026

Day 1 is the day you start it.

Phase 1 (Viking release, Mar-28-2023), phase 2 VENTURE RCT (Bays 2026, Obesity; NCT06068946), Viking updates Feb-11-2026 and Oct-28-2026, VANQUISH records on ClinicalTrials.gov. Investigational.

Moderate evidence

## More on VK2735

### Dose Guide

- [VK2735 dose guide](https://pepvault.app/lab/dosage/vk2735)

### Mixing charts

- [10 mg vial](https://pepvault.app/tools/reconstitution-calculator/vk2735-10mg)

### Studies

- [VK2735: up to 14.7% weight loss at 13 weeks in VENTURE](https://pepvault.app/research/vk2735-venture-2026)
- [The study on the research page](https://pepvault.app/research#vk2735)

### Compared with

- [Tirzepatide vs VK2735](https://pepvault.app/peptides/compare/tirzepatide-vs-vk2735)
- [Retatrutide vs VK2735](https://pepvault.app/peptides/compare/retatrutide-vs-vk2735)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [How the vial count works](https://pepvault.app/peptide-vial-tracker-app)

### Terms on this page

- [Peptide](https://pepvault.app/glossary/peptide)
- [Bacteriostatic water](https://pepvault.app/glossary/bacteriostatic-water)
- [U-100 syringe](https://pepvault.app/glossary/u-100-syringe)
- [Unit (on a syringe)](https://pepvault.app/glossary/syringe-units)
- [Subcutaneous (SubQ)](https://pepvault.app/glossary/subcutaneous)
- [Half-life](https://pepvault.app/glossary/half-life)
- [Stack](https://pepvault.app/glossary/stack)
- [GLP-1](https://pepvault.app/glossary/glp-1)

## Mixing and a typical run.

Example numbers

### Reconstitution example

Reconstitute a 10 mg vial of VK2735 with 2 mL of bacteriostatic water and a 2.5 mg dose is 50 units on a U-100 syringe, about 4 doses per vial.

- **Vial:** 10 mg
- **Water:** 2 mL
- **Amount:** 2.5 mg

Draw to **50 units**

0.5 mL insulin syringe · 50 units

[Mix it in the Reconstitution Lab](https://pepvault.app/lab) [Open the calculator](https://pepvault.app/tools/reconstitution-calculator)

### Run notes

- **Cycle:** Used continuously, once weekly, in its trials: 13 weeks in phase 2 and 78 weeks in phase 3. In Viking's maintenance study, people who switched after 21 weekly doses to a shot every other week or once a month kept most of their loss over the next 12 weeks; on placebo they kept about 61%. Community practice — opinions vary. Not a clinical recommendation.
- **Timing:** Once weekly SubQ, same day each week, in its trials. VENTURE started at 2.5 mg (5 mg for its 15 mg group) and stepped up every 3 weeks to 5, 10 or 15 mg; phase 3 tests 7.5, 12.5 and 17.5 mg. The tablet is a daily dose in its own trials (27.5 to 55 mg in phase 3), not interchangeable mg for mg with the shot. These are trial schedules, not an approved regimen.
- **Route:** SubQ injection
- **Stacks:** BPC-157 (GI support)

<!--promo-->

[Track it in the app](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=peptides-next-mixing&mt=8)

<!--/promo-->

## Safety.

### Common side effects

- Nausea
- Constipation
- Diarrhea
- Vomiting
- Acid reflux
- Fatigue
- Dry mouth

#### Interactions

No interaction studies have been published. GLP-1 drugs slow stomach emptying, which can change how oral medicines are absorbed. It is a GLP-1 drug itself, so it is not stacked with another one. With insulin or a sulfonylurea, discuss glucose monitoring with your clinician.

### Safety notes

VK2735 has no label: it is still in trials. In the 13-week phase 2 VENTURE trial, GI side effects affected 51% to 83% across doses vs 37% on placebo, mostly mild or moderate, early, and fading over time; nausea was highest in the first week of the 15 mg group, the only one started at 5 mg instead of 2.5 mg. 9.1% stopped the drug for side effects (none on placebo), most often for nausea or vomiting. It is a GLP-1 drug, so the class warnings in GLP-1 labels (including pancreatitis, gallbladder disease and the rodent thyroid C-cell finding) are the ones to read. These are trial findings to review with your clinician.

## Goes with.

- [BPC-157 GI support](https://pepvault.app/peptides/bpc-157)

## One question at a time.

- [Half-life](https://pepvault.app/peptides/vk2735/half-life)
- [Side effects](https://pepvault.app/peptides/vk2735/side-effects)
- [How long it takes to work](https://pepvault.app/peptides/vk2735/how-long-to-work)
- [Legal status](https://pepvault.app/peptides/vk2735/legal-status)

## Compared with.

- [Tirzepatide vs VK2735](https://pepvault.app/peptides/compare/tirzepatide-vs-vk2735)
- [Retatrutide vs VK2735](https://pepvault.app/peptides/compare/retatrutide-vs-vk2735)

## Mixing charts by vial size.

- [10 mg vial](https://pepvault.app/tools/reconstitution-calculator/vk2735-10mg)

## Studies, in plain English.

- [VK2735: up to 14.7% weight loss at 13 weeks in VENTURE](https://pepvault.app/research/vk2735-venture-2026)
- [Every study on VK2735](https://pepvault.app/research#vk2735)

## Questions people ask.

### What is VK2735?

A weekly GLP-1 and GIP dual agonist from Viking Therapeutics, the same two-receptor approach as tirzepatide, also being tested as a daily tablet. In its 13-week phase 2 trial, people lost about 9% to 15% of their body weight depending on the dose, with no sign of levelling off.

### How is VK2735 dosed in research?

The research range for VK2735 is 2.5–17.5 mg, weekly, with a 2.5 mg starting dose. Studied in research — not a recommendation.

### How long does VK2735 last?

The half-life of VK2735 is ~9 days (measured in people: 170–250 hours after single doses, Viking phase 1, 2023).

### What do people report on VK2735?

Commonly reported on VK2735: in trials, nausea and other GI effects early on, fading as the dose holds. It is in phase 3 and not approved anywhere.

### Is VK2735 safe?

The research basis for VK2735 is moderate: animal studies + some human data. Common side effects in the library: nausea, constipation, diarrhea, vomiting, acid reflux, fatigue and dry mouth.

### What does VK2735 stack with?

Common stacks for VK2735: BPC-157 (GI support).

<!--promo-->

[Track it in the app](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=peptides-next-questions&mt=8)

<!--/promo-->

## Research.

The literature

### Search the latest research

[PubMed](https://pubmed.ncbi.nlm.nih.gov/?term=VK2735) [Google Scholar](https://scholar.google.com/scholar?q=VK2735)

## Reference.

- **Cadence:** Weekly
- **Half-life:** ~9 days ~9 days (measured in people: 170–250 hours after single doses, Viking phase 1, 2023)
- **Research basis:** Moderate Animal studies + some human data

## More metabolic & glp-1 peptides

- [Enicepatide 4–24 mg](https://pepvault.app/peptides/enicepatide)
- [Ecnoglutide 0.6–2.4 mg](https://pepvault.app/peptides/ecnoglutide)
- [Efinopegdutide 4–10 mg](https://pepvault.app/peptides/efinopegdutide)
- [5-Amino-1MQ 50–100 mg](https://pepvault.app/peptides/5-amino-1mq)
- [SLU-PP-332 250–1000 mcg](https://pepvault.app/peptides/slu-pp-332)
- [Oxytocin 10–40 IU](https://pepvault.app/peptides/oxytocin)

## Free tools

- [VK2735 dose guide](https://pepvault.app/lab/dosage/vk2735)
- [Reconstitution Lab (3D)](https://pepvault.app/lab)
- [Injection guide (3D)](https://pepvault.app/lab/injection)
- [Peptide Sky (3D)](https://pepvault.app/lab/sky)
- [Peptide tier list](https://pepvault.app/lab/tiers)
- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [Half-life & active level](https://pepvault.app/tools/peptide-half-life-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)

<!--promo-->

PepVault for iPhone

## Track VK2735 in PepVault

Log each dose, see how many doses are left in the vial, and keep your step-ups in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=peptides-card-end&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

<!--promo-->

Model. Individual results vary.

PepVault for iPhone

## Track VK2735 in PepVault

Log each dose, see how many doses are left in the vial, and keep your step-ups in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=peptides-card-rail&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## More on VK2735

### Dose Guide

- [VK2735 dose guide](https://pepvault.app/lab/dosage/vk2735)

### Mixing charts

- [10 mg vial](https://pepvault.app/tools/reconstitution-calculator/vk2735-10mg)

### Studies

- [VK2735: up to 14.7% weight loss at 13 weeks in VENTURE](https://pepvault.app/research/vk2735-venture-2026)
- [The study on the research page](https://pepvault.app/research#vk2735)

### Compared with

- [Tirzepatide vs VK2735](https://pepvault.app/peptides/compare/tirzepatide-vs-vk2735)
- [Retatrutide vs VK2735](https://pepvault.app/peptides/compare/retatrutide-vs-vk2735)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [How the vial count works](https://pepvault.app/peptide-vial-tracker-app)

### Terms on this page

- [Peptide](https://pepvault.app/glossary/peptide)
- [Bacteriostatic water](https://pepvault.app/glossary/bacteriostatic-water)
- [U-100 syringe](https://pepvault.app/glossary/u-100-syringe)
- [Unit (on a syringe)](https://pepvault.app/glossary/syringe-units)
- [Subcutaneous (SubQ)](https://pepvault.app/glossary/subcutaneous)
- [Half-life](https://pepvault.app/glossary/half-life)
- [Stack](https://pepvault.app/glossary/stack)
- [GLP-1](https://pepvault.app/glossary/glp-1)

<!--promo-->

PepVault for iPhone

## Track VK2735 in PepVault

Log each dose, see how many doses are left in the vial, and keep your step-ups in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=peptides-card-sticky&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

Reviewed November 2026 [How we check the library](https://pepvault.app/about#library)

PepVault is a research and tracking resource, not medical advice. Ranges are what studies used, never a dose for you. Brand names are trademarks of their owners; PepVault is independent of them.

PepVault is a private research and tracking tool, not medical advice. The information here is reference material from published literature and community use — always verify it and discuss any protocol with a qualified clinician before changing it.

© 2026 PepVault. Our text, data and tools may not be copied, scraped or republished without [permission](https://pepvault.app/terms#content).
